Across 113 reviewed trials, digital or remote recruitment was documented in a minority of Phase III breast cancer studies, while registry or advocacy-linked recruitment appeared even less often. The signal is not that digital recruitment has become standard, but that it is selectively used in more operationally ambitious trials with broader outreach architecture.
Digital or remote recruitment appeared in 13.3% of reviewed trials. The field remains selective rather than routine: most trials still relied on conventional site-based recruitment, standard patient materials, or no explicit recruitment methods in the extracted data.
Digital recruitment is not yet a default feature in European breast cancer Phase III submissions. The increase after 2024 suggests wider experimentation, but the overall level remains low enough that digital outreach can still differentiate trial execution strategy.
Registry or advocacy-linked recruitment was documented in 10.6% of reviewed trials. The stronger 2026 signal suggests that registry or patient-organisation involvement may be becoming more visible in selected trial dossiers, especially where long enrollment windows or large target populations require broader access routes.
Registry and advocacy channels remain uncommon but strategically important. When present, they appear less like generic awareness tools and more like infrastructure for patient identification, retention support, or disease-community access.
The most visible outreach components were still conventional printed materials, but digital-enabled trials often layered websites, landing pages, online postings, social media, patient letters, recruitment vendors, QR/video assets, and consent-support tools. This suggests digital recruitment is most often added as part of a broader recruitment architecture rather than as a standalone tactic.
The operational opportunity is not just “add a website.” The more mature recruitment packages combine patient-facing digital assets, physician referral routes, local printed materials, consent support, and retention infrastructure.
Trials with digital recruitment had a higher median planned sample size than trials without digital recruitment. Registry or advocacy-linked trials showed an even larger median planned sample size and a longer median recruitment window, suggesting these channels are used more often where enrollment pressure is structurally higher.
The strongest operational signal is scale. Digital and registry-linked strategies appear more often where enrollment demand is larger, but their limited overall adoption suggests many large trials may still be underusing broader patient-access infrastructure.
European Phase III breast cancer trials are not yet consistently built around digital patient access. Most dossiers still show conventional recruitment architecture, while digital, registry, and advocacy-linked approaches are concentrated in a subset of larger or more complex trials.
For medical directors and CMOs, recruitment strategy should be treated as part of evidence-generation design. If a Phase III breast cancer program depends on narrow molecular eligibility, long recruitment windows, broad geographic reach, or competitive treatment sequencing, patient-access infrastructure should be planned early rather than added reactively after enrollment underperformance.